|
1
|
Safety and tolerability of intraputaminal delivery of CERE-120 (adeno-associated virus serotype 2-neurturin) to patients with idiopathic Parkinson's disease: an open-label, phase I trial.
|
Lancet Neurol
|
2008
|
4.16
|
|
2
|
Gene delivery of AAV2-neurturin for Parkinson's disease: a double-blind, randomised, controlled trial.
|
Lancet Neurol
|
2010
|
3.84
|
|
3
|
Disease duration and the integrity of the nigrostriatal system in Parkinson's disease.
|
Brain
|
2013
|
2.09
|
|
4
|
Delivery of neurturin by AAV2 (CERE-120)-mediated gene transfer provides structural and functional neuroprotection and neurorestoration in MPTP-treated monkeys.
|
Ann Neurol
|
2006
|
1.46
|
|
5
|
The role of leukocytes following cerebral ischemia: pathogenic variable or bystander reaction to emerging infarct?
|
Exp Neurol
|
2002
|
1.27
|
|
6
|
Insulin growth factor-1 gene transfer enhances neurovascular remodeling and improves long-term stroke outcome in mice.
|
Stroke
|
2008
|
1.22
|
|
7
|
Intraparenchymal spinal cord delivery of adeno-associated virus IGF-1 is protective in the SOD1G93A model of ALS.
|
Brain Res
|
2007
|
1.20
|
|
8
|
AAV2-mediated delivery of human neurturin to the rat nigrostriatal system: long-term efficacy and tolerability of CERE-120 for Parkinson's disease.
|
Neurobiol Dis
|
2007
|
1.15
|
|
9
|
Striatal delivery of CERE-120, an AAV2 vector encoding human neurturin, enhances activity of the dopaminergic nigrostriatal system in aged monkeys.
|
Mov Disord
|
2007
|
1.10
|
|
10
|
Expression, bioactivity, and safety 1 year after adeno-associated viral vector type 2-mediated delivery of neurturin to the monkey nigrostriatal system support cere-120 for Parkinson's disease.
|
Neurosurgery
|
2009
|
1.10
|
|
11
|
Striatal delivery of neurturin by CERE-120, an AAV2 vector for the treatment of dopaminergic neuron degeneration in Parkinson's disease.
|
Mol Ther
|
2007
|
1.06
|
|
12
|
The Alcohol Clinical Trials Initiative (ACTIVE): purpose and goals for assessing important and salient issues for medications development in alcohol use disorders.
|
Neuropsychopharmacology
|
2011
|
0.96
|
|
13
|
Viral delivery of glial cell line-derived neurotrophic factor improves behavior and protects striatal neurons in a mouse model of Huntington's disease.
|
Proc Natl Acad Sci U S A
|
2006
|
0.96
|
|
14
|
Postischemic IGF-1 gene transfer promotes neurovascular regeneration after experimental stroke.
|
J Cereb Blood Flow Metab
|
2009
|
0.95
|
|
15
|
Transgene expression, bioactivity, and safety of CERE-120 (AAV2-neurturin) following delivery to the monkey striatum.
|
Mol Ther
|
2008
|
0.94
|
|
16
|
Intraspinal cord delivery of IGF-I mediated by adeno-associated virus 2 is neuroprotective in a rat model of familial ALS.
|
Neurobiol Dis
|
2008
|
0.91
|
|
17
|
Intrastriatal CERE-120 (AAV-Neurturin) protects striatal and cortical neurons and delays motor deficits in a transgenic mouse model of Huntington's disease.
|
Neurobiol Dis
|
2008
|
0.89
|
|
18
|
Therapeutic potential of CERE-110 (AAV2-NGF): targeted, stable, and sustained NGF delivery and trophic activity on rodent basal forebrain cholinergic neurons.
|
Exp Neurol
|
2008
|
0.88
|
|
19
|
Enhanced neurotrophic distribution, cell signaling and neuroprotection following substantia nigral versus striatal delivery of AAV2-NRTN (CERE-120).
|
Neurobiol Dis
|
2013
|
0.86
|
|
20
|
Sustained release chemotherapeutic microspheres provide superior efficacy over systemic therapy and local bolus infusions.
|
Pharm Res
|
2002
|
0.86
|
|
21
|
Bradykinin receptor agonist facilitates low-dose cyclosporine-A protection against 6-hydroxydopamine neurotoxicity.
|
Brain Res
|
2002
|
0.81
|
|
22
|
Neurturin gene therapy improves motor function and prevents death of striatal neurons in a 3-nitropropionic acid rat model of Huntington's disease.
|
Neurobiol Dis
|
2007
|
0.80
|
|
23
|
Neutron capture therapy of intracerebral melanoma: enhanced survival and cure after blood-brain barrier opening to improve delivery of boronophenylalanine.
|
Int J Radiat Oncol Biol Phys
|
2002
|
0.79
|
|
24
|
Inhibitors of cyclooxygenase-2, but not cyclooxygenase-1 provide structural and functional protection against quinolinic acid-induced neurodegeneration.
|
J Pharmacol Exp Ther
|
2003
|
0.77
|
|
25
|
Gene transfer provides a practical means for safe, long-term, targeted delivery of biologically active neurotrophic factor proteins for neurodegenerative diseases.
|
Drug Deliv Transl Res
|
2011
|
0.77
|
|
26
|
Injection of chemotherapeutic microspheres and glioma. IV: Eradicating tumors in rats.
|
Cell Transplant
|
2002
|
0.77
|
|
27
|
Injection of chemotherapeutic microspheres and glioma. III: Parameters to optimize efficacy.
|
Cell Transplant
|
2002
|
0.75
|